Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Research & Development readings, the most recent being $8.0 million for Q1 2026.

  • Quarterly Research & Development rose 41.21% to $8.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.9 million through Mar 2026, up 28.08% year-over-year, with the annual reading at $24.6 million for FY2025, 29.16% up from the prior year.
  • Research & Development hit $8.0 million in Q1 2026 for DiaMedica Therapeutics, up from $6.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.0 million in Q1 2026 and bottomed at $1.6 million in Q3 2022.
  • Average Research & Development over 5 years is $4.3 million, with a median of $3.7 million recorded in 2023.
  • The largest annual shift saw Research & Development dropped 29.67% in 2022 before it skyrocketed 99.51% in 2023.
  • DiaMedica Therapeutics' Research & Development stood at $2.3 million in 2022, then soared by 61.98% to $3.7 million in 2023, then skyrocketed by 75.96% to $6.5 million in 2024, then rose by 3.54% to $6.7 million in 2025, then rose by 19.23% to $8.0 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Research & Development are $8.0 million (Q1 2026), $6.7 million (Q4 2025), and $6.4 million (Q3 2025).